PT524 – Building a Unified Psychedelic Future: Ethics, Standards, and a Path to Affordable Access, with Lia Mix, LMFT, CPTR
Jun 25, 2024
auto_awesome
Lia Mix discusses the need for a unified code of ethics in psychedelic therapy, the FDA's role in the field, and the financial potential of investing in psychedelic healthcare. She highlights the importance of regulations, certifications, and consumer protections to ensure safe integration into the healthcare system.
Unity in psychedelic community vital for establishing ethical standards in therapy.
Financial potential in psychedelic industry if essential standards are agreed upon.
Acknowledging fears and shadows crucial in developing unified standards for safe psychedelic therapy.
Deep dives
Leah Mix's Diverse Background and Influence in Psychedelia
Leah Mix, a prominent figure in the psychedelic space, discusses her diverse background and experiences, including being a therapist and working in the healthcare system, providing insights into the challenges and importance of unity in psychedelic projects.
Implementing Transformative Training in Integrative Psychedelic Studies
A 12-month certificate program, Vital, offers a comprehensive curriculum integrating clinical, scientific, and spiritual domains, emphasizing a community of students committed to personal growth and professional development in the psychedelic field.
Overcoming Barriers in Access to Care: Leah's Impact on Autism Coverage
Leah Mix shares her instrumental role in expanding insurance coverage for applied behavior analysis, a crucial treatment for autism, highlighting the complexities and successes in addressing access to care in healthcare systems.
Navigating Healthcare Systems and Regulatory Interfaces
Leah delves into her experience in advocating for change within the commercial health insurance industry, emphasizing the importance of aligning legislation, policies, and provider networks to enhance access to care and support new clinical specialties.
Addressing Fear and Shadow Work in Psychedelic Healthcare
Leah delves into the FDA advisory committee meeting, emphasizing the importance of acknowledging and addressing fears and shadows within the psychedelic field, advocating for unified standards, ethics, and practitioner organizations to ensure safe, effective, and accessible psychedelic therapy.
In this episode, Joe interviews Lia Mix, LMFT, CPTR: founder and CEO of Delphi, a consulting firm dedicated to the healthy growth of the psychedelic movement.
After many years of working in community mental health and 15 years in the commercial health insurance industry (where she helped to establish coverage for autism), Mix was one of the first graduates of CIIS’s training program, and after a very distinct MDMA-assisted therapy session, she wondered: “How can I be of service?” She’s since helped to launch The Board of Psychedelic Medicines and Therapies, the American Psychedelic Practitioners Association, and Enthea, and is working every day toward a more unified and uniform psychedelic space, with healthcare frameworks, official boards and certifications, consumer protections, and a general consensus that this is our responsibility to manage – not some outside regulator’s. So how can we, as a scattered psychedelic community, come together?
She discusses:
Her path to psychedelics and how nobody was talking about how to bring psychedelics into healthcare
The need for a unified code of ethics for any practitioner of psychedelic therapy
The FDA, Lykos Therapeutics, and how the recent advisory committee’s recommendations on MDMA-assisted psychotherapy were largely based on fear
How there actually is a lot of financial possibility if we can all agree on what is absolutely essential right now